All In Biotech

Drug Trial Radar · NCT02324270

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

Randomized, Double-Blind, Multiple-Center, Placebo-Controlled Study Comparing the Safety and Efficacy of Generic Diclofenac Epolamine to Flector® Patch in the Treatment of Acute Pain Due to Minor Ankle Sprain

Last checked: Nov 20, 2026Latest source record: Jun 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 658 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

658

Actual

Start

May 2014

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Dec 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain

Conditions

  • Ankle Sprain

Interventions

  • Diclofenac epolamineDrug

    Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain

  • PlaceboOther

    Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Analogue Scale (VAS) Scores at Baseline and Post TreatmentTime frame: Baseline, 3 days

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Site 21

    Birmingham, Alabama

  • Site 24

    Goodyear, Arizona

  • Site 08

    Carlsbad, California

  • Site 05

    Ventura, California

  • Site 16

    Clinton, Connecticut

  • Site 03

    Riverton, Connecticut

  • Site 11

    Daytona Beach, Florida

  • Site 09

    DeLand, Florida

  • Site 14

    Miami, Florida

  • Site 07

    Miami, Florida

  • Site 13

    Miami, Florida

  • Site 02

    West Palm Beach, Florida

  • Site 26

    Lexington, Kentucky

  • Site 12

    Gretna, Louisiana

  • Site 23

    Kalamazoo, Michigan

  • Site 41

    Traverse City, Michigan

  • Site 10

    Omaha, Nebraska

  • Site 29

    Berlin, New Jersey

  • Site 18

    Brooklyn, New York

  • Site 19

    Cincinnati, Ohio

  • Site 30

    Columbus, Ohio

  • Site 35

    Oklahoma City, Oklahoma

  • Site 37

    Downingtown, Pennsylvania

  • Site 27

    State College, Pennsylvania

  • Site 15

    Austin, Texas

  • 04

    El Paso, Texas

  • Site 34

    Houston, Texas

  • Site 36

    Lake Jackson, Texas

  • Site 22

    San Antonio, Texas

  • Site 31

    Danville, Virginia

  • Site 06

    Newport News, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.